Cefazolin

Generic Name: Cefazolin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₄N_₈O_₄S_₃

CAS Number: 25953-19-9

Unique Ingredient Identifier: IHS69L0Y4T

Background: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Indication: Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis.

Associated Conditions: Bacterial Septicemia caused by susceptible Bacterial Infections, Biliary tract infection bacterial caused by susceptible Bacterial Infections, Bone and Joint Infections caused by susceptible Bacterial Infections, Catheter-related Bloodstream Infection (CRBSI) NOS, Community Acquired Pneumonia (CAP), Endocarditis caused by susceptible Bacterial Infections, Genital infection caused by susceptible Bacterial Infections, Osteoarticular Infections, Postoperative Infections, Respiratory Tract Infection Bacterial caused by susceptible Bacterial Infections, Skin and Soft Tissue Infections (SSTIs), Skin and Subcutaneous Tissue Infection caused by susceptible Bacterial Infections, Susceptible infections, Urinary Tract Infection caused by susceptible Bacterial Infections, Perioperative infection, Susceptible Bacterial Infections

Associated Therapies: Antibiotic pre-surgical prophylaxis

Clinical Trials

Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial

Phase 4

Not yet recruiting

Conditions: Infection, Surgical Site

Interventions: Drug: Cefazolin
Drug: Vancomycin

First Posted Date: 2024-08-23

Last Posted Date: 2024-08-23

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 38000

Registration Number: NCT06567808

Results of Extended Versus Single Dose Antibiotic Prophylaxis In Orthopedic Revision Arthroplasty in Nijmegen.

Phase 3

Active, not recruiting

Conditions: Infection Prosthesis Hip and Knee
Infection, Prosthesis Related
Joint Infection
Infection, Surgical Site
Infection Pro
Surgical Site Infection

Interventions: Drug: Cefazolin

First Posted Date: 2024-05-07

Last Posted Date: 2024-05-07

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 751

Registration Number: NCT06402591

Locations: 🇳🇱
Radboudumc, Nijmegen, Gelderland, Netherlands

Antibiotic Prophylaxis in Pediatric Open Fractures

Phase 4

Conditions: Fractures, Open
Infections

Interventions: Drug: Cefazolin
Drug: Cephalexin

First Posted Date: 2023-09-28

Last Posted Date: 2024-10-08

Lead Sponsor: St. Louis University

Target Recruit Count: 800

Registration Number: NCT06055712

Locations: 🇺🇸
Saint Louis University, Saint Louis, Missouri, United States

Timing of Maternal Antibiotic Prophylaxis During a Cesarean Section and the Early Infant Gut Microbiome

Not Applicable

Completed

Conditions: Cesarean Section Complications
Microbial Colonization
Antibiotic Side Effect

Interventions: Drug: Cefazolin

First Posted Date: 2023-09-11

Last Posted Date: 2023-09-13

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 33

Registration Number: NCT06030713

Locations: 🇳🇱
University Medical Center Groningen, Groningen, Netherlands

Comparing of Cefazolin Plus Azithromycin Versus Cefazolin in Prevention of Febrile Morbidity After Emergency Cesarean Delivery

Not Applicable

Completed

Conditions: Febrile Morbidity After Emergency Cesarean Section

Interventions: Drug: Azithromycin Injection [Zithromax]
Drug: Cefazolin
Drug: Sodium Chloride 0.9% Intravenous Solution

First Posted Date: 2022-12-13

Last Posted Date: 2024-01-25

Lead Sponsor: Rajavithi Hospital

Target Recruit Count: 172

Registration Number: NCT05647993

Locations: 🇹🇭
Rajavithi Hospital, Bangkok, Thailand

Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study

Phase 4

Recruiting

Conditions: Surgical Site Infection

Interventions: Drug: Cefazolin
Drug: Water for injection

First Posted Date: 2022-07-07

Last Posted Date: 2024-11-22

Lead Sponsor: Monash University

Target Recruit Count: 9180

Registration Number: NCT05447559

Locations: 🇦🇺
Sir Charles Gairdner, Nedlands, Western Australia, Australia
🇦🇺
Fiona Stanley Hospital, Perth, Western Australia, Australia
🇦🇺
St Vincent's Hospital, Melbourne, Australia

and more 19 locations

Cefazolin PK Study 3g vs 2g

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cefazolin

First Posted Date: 2022-04-04

Last Posted Date: 2022-10-12

Lead Sponsor: Baxter Healthcare Corporation

Target Recruit Count: 24

Registration Number: NCT05309304

Locations: 🇺🇸
Baxter Investigational Site, Baltimore, Maryland, United States

Randomized Assessment of Antibiotic Prophylaxis Prior to Port Placement

Not Applicable

Withdrawn

Conditions: Vascular Access Ports

Interventions: Drug: Cefazolin
Other: saline

First Posted Date: 2022-03-31

Last Posted Date: 2024-04-26

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Registration Number: NCT05304871

Staphylococcus Aureus Network Adaptive Platform Trial

Phase 4

Recruiting

Conditions: Staphylococcus Aureus Bacteremia

Interventions: Radiation: Whole body FDG PET/CT Imaging
Drug: Penicillin
Other: Effectiveness of early switch to oral antibiotics
Drug: Cefazolin
Drug: Clindamycin
Drug: Vancomycin

First Posted Date: 2021-11-30

Last Posted Date: 2024-06-05

Lead Sponsor: University of Melbourne

Target Recruit Count: 8000

Registration Number: NCT05137119

Locations: 🇦🇺
Cairns Hospital, Cairns, Queensland, Australia
🇨🇦
Hôpital Régional de Saint Jérôme, Saint-Jérôme, Quebec, Canada
🇳🇱
Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands

and more 146 locations

The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma

Phase 1

Active, not recruiting

Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8
Clinical Stage IA Cutaneous Melanoma AJCC v8
Clinical Stage IIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIC Cutaneous Melanoma AJCC v8
Pathologic Stage I Cutaneous Melanoma AJCC v8
Pathologic Stage IB Cutaneous Melanoma AJCC v8
Pathologic Stage IIA Cutaneous Melanoma AJCC v8
Clinical Stage IB Cutaneous Melanoma AJCC v8
Clinical Stage II Cutaneous Melanoma AJCC v8

Interventions: Drug: Cefazolin
Procedure: Resection

First Posted Date: 2021-05-06

Last Posted Date: 2024-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT04875728

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy